BioWorld

March 22, 2005

Onyx, Bayer Plan To File NDA For Sorafenib On Interim Data

Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. plan to file for FDA approval of BAY 43-9006, which has been renamed sorafenib, based on interim Phase IIII data from a study in advanced kidney cancer patients. (BioWorld Today) Read More

Sequoia Raises $22M To Fund Programs In Viral Infections

Avastin Competitor Misses Endpoint; Genentech Jumps

Biolex Signs Up Centocor In Wide-Ranging Protein Deal

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...